Kymera Therapeutics (KYMR) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St futures slide as rising oil, yields dampen mood
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Join SI Premium – FREE
Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.58), $0.10 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $25.7 million versus the consensus estimate of $12.55 million.
For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Saratoga Investment (SAR) PT Lowered to $18 at Compass Point
- Helen of Troy (HELE) Tops Q2 EPS by 28c, Misses on Revenue; Offers FY27 Guidance
- AngioDynamics (ANGO) Tops Q1 EPS by 7c, Beats on Revenue; Offers F27 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
